Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases.

ABSTRACT: Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy. In many cases this biological treatment stopped the progression of the disease, probably also decreasing morbidity and hospitalization rates, and improving patients' comfort. When the patent on infliximab started to expire, the first biosimilar of a monoclonal antibody was introduced onto the pharmacological market. Biosimilar infliximab was studied in rheumatology and proved a high similarity to the reference drug. Based on extrapolation, biosimilars were approved to treat adult and paediatric IBD patients. Biosimilar infliximab, mainly because of its lower

SUBMITTER: Sieczkowska J 

PROVIDER: S-EPMC4984328 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature